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Management and prevention of cardiovascular disease 
(CVD) represents one of the major health challenges 
worldwide. CVD is the leading cause of death globally 
despite all research efforts on last decades regarding the 
molecular mechanisms and processes involved on its 
development and progression. Chronic Kidney Disease 
(CKD) is an independent risk factor and promotor of 
CVD events, representing a considerable economic cost 
for the health system. CVD is the leading cause of death 
in all CKD stages, accounting for half the number of 
deaths in this population. In fact, cardiovascular risk is 
still incompletely explained by traditional risk factors, 
and risk factors such as increased chronic inflammation 
and vascular calcification (VC) have been identified as 
valuable prognostic tools for cardiovascular risk assess-
ment [1]. Indeed, in the current view that highlights the 
complexity of CVD, inflammation and VC cannot be 
considered only hallmarks, but also drivers of disease 
progression functioning in a positive feed-back loop 
through a complex interplay with bidirectional crosstalk 
factors that influence CVD progression and outcomes 
[2]. A better understanding of this complex network and 
the discovery of new modulating agents targeting both 
inflammation and calcification, will pave the way to the 
discovery of new biomarkers and novel therapeutic 
strategies for cardiovascular-associated diseases. Gla-
rich protein (GRP), a vitamin K-dependent protein, was 
shown to function as a calcification inhibitor in the 
cardiovascular system and as an anti-inflammatory 
agent in articular and immune cells [3, 4, 5], opening  
new perspectives for a crucial and global function as a 
modulator of calcification-related chronic inflammatory 
diseases such as CVD. Although GRP-deficient mice 
did not display a significant impairment in skeletal 
development, it was clearly demonstrated that vascular 
smooth muscle cells (VSMCs) from GRP-/- mice, when 
exposed to calcifying conditions, have increased 
mineralization and expression of osteo/chondrogenic 
markers [6].  In addition to the inhibition of calcifica-
tion at tissue level, we found that GRP is a constitutive 
component of circulating calciprotein particles (CPPs) 
and extracellular vesicles (EVs), and demonstrated that 
GRP is a systemic inhibitor of ectopic calcification 
through its involvement on the inhibition of Ca/P 
mineral crystal formation and maturation in blood, with 
profound consequences on VC [7]. In fact, although the 
role of mineral-containing  EVs  released  from  VSMCs 








has been recently highlighted as a nidus of calcification, 
the role and significance of circulating EVs in vascular 
calcification is still largely unknown. Also, the for-
mation of CPPs has been suggested as a defense 
mechanism against Ca/P precipitation in blood, thereby 
capable of maintaining blood mineral homeostasis and 
prevent calcification [8]. Moreover, CPPs have attracted 
recent attention in clinical and basic research as a new 
molecular marker involved in CKD pathology. While 
several in vitro experiments have shown a deleterious 
effect of synthetic CPPs in cultured cells by promoting 
inflammatory and mineralization responses, we have 
shown that biological CPPs and EVs, isolated from 
CKD serum have an increased potential to induce 
calcification and inflammation in VSMCs. The capacity 
of these pathogenic circulating entities to promote VC is 
explained by a deficiency of GRP and fetuin-A, and a 
consequent increase in mineral maturation, when 
compared with nanoparticles from control healthy 
subjects [7]. Furthermore, removal of EVs from healthy 
serum clearly promoted VC, suggesting that these cir-
culating nanoparticles containing higher levels of GRP 
and fetuin-A constitute a powerful anti-mineralization 
system that is able to regulate mineral formation both at 
systemic and tissue levels [7]. The relation between 
GRP levels in circulating EVs with CKD pathology and 
vascular calcification is certain of noteworthy impor-
tance from a translational perspective. EVs can be 
found in various tissues and fluids and considered to 
have an essential function in intercellular communica-
tion. They have also been regarded as attractive 
diagnostic biomarkers and their therapeutic use is an 
emerging field. While we previously demonstrated the 
presence of GRP in VSMCs and macrophage-released 
EVs, and its involvement in the mineralization-com-
petence of VSMCs-derived EVs [3, 4], we further 
shown that decreased levels of GRP in circulating EVs 
from CKD patients are correlated with increased 
pathogenicity of these nanostructures [7]. Although 
many questions are still opened and additional efforts 
are required to understand a possible relation between 
loading of circulating EVs and vascular health, from a 
biomarker perspective the lower levels of GRP in 
circulating EVs and CPPs foresee a potential applica-
tion in CKD diagnostic and beyond. 
Importantly, the dual capacity of GRP to act as an anti-
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calcification, was clearly demonstrated when the 
calcification/osteogenic differentiation and inflamma-
tory status induced in VSMCs was rescued by sup-
plementation of CPPs isolated from CKD patients with 
GRP [7]. This is in line with previous functional studies 
in human in vitro systems, showing that increasing GRP 
levels decrease extracellular matrix calcification and 
pro-inflammatory responses [3, 4, 5], strongly suggest-
ing GRP as a potential therapeutic target for CVD. 
Overall, we propose that GRP is a crucial component of 
a powerful anti-mineralization mechanism to regulate 
the dynamics of mineral formation both at systemic and 
tissue levels, to prevent pathological deposition of 
mineral and disease amplification through an increase in 
the inflammatory status. We are currently further 
exploring the role and mechanism of action of GRP as 
an anti-inflammatory agent on CVD. Since the interplay 
between calcification and inflammatory events are 
determinant processes to the development of CVD, 
possible approaches targeting the increase of GRP bio-
availability might represent promising therapeutic 
options for vascular calcification-related diseases, and 
the determination of GRP levels in circulation should 
became a valuable tool for global cardiovascular risk 
assessment. 
    
REFERENCES 
 
1.   Benz  K,  et  al.  Int  J  Nephrol.  2018;  2018:4310379. 
https://doi.org/10.1155/2018/4310379 
2.   Viegas CS, Simes DC. Book Chapter 15  in  "Immunity 







4.   Viegas  CS,  et  al.  PLoS  One.  2017;  12:e0177829. 
https://doi.org/10.1371/journal.pone.0177829 
5.   Cavaco S, et al. Cell Mol  Life  Sci. 2016; 73:1051–65. 
https://doi.org/10.1007/s00018‐015‐2033‐9 





8.   Smith  ER,  et  al.  Bone.  2018;  110:355–67. 
https://doi.org/10.1016/j.bone.2018.02.023 
 






vascular  calcification  and  inflammation,  extracellular 
vesicles (EVs), calciprotein particles (CPPs) 
Copyright: Viegas and Simes. This is an open‐access article 
distributed  under  the  terms  of  the  Creative  Commons 
Attribution License (CC BY 3.0), which permits unrestricted 






www.aging‐us.com                   1324                                                                             AGING
